Stefanie Thevelin1, Leïla El Mounaouar2, Sophie Marien3,4, Benoit Boland3,4, Séverine Henrard5,4, Olivia Dalleur5,6. 1. Clinical Pharmacy Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Avenue Mounier 72 bte B1.72.02, 1200, Brussels, Belgium. stefanie.thevelin@uclouvain.be. 2. Medical School, Université catholique de Louvain, Brussels, Belgium. 3. Department of Geriatric Medicine, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium. 4. Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium. 5. Clinical Pharmacy Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Avenue Mounier 72 bte B1.72.02, 1200, Brussels, Belgium. 6. Pharmacy Department, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
Abstract
BACKGROUND: Older persons are at significant risk of drug-related admissions (DRAs). We previously demonstrated that 27% of hospitalizations in geriatric patients were associated with potentially inappropriate medicines (PIMs) and/or potential prescribing omissions (PPOs) identified by the Screening Tool of Older People's Prescriptions/Screening Tool to Alert to Right Treatment (STOPP/START) criteria version 1 (v1). The updated STOPP/START criteria version 2 (v2) comprised a 31% increase in prescribing criteria. OBJECTIVE: As a secondary analysis of our study conducted in 2008, we aimed to compare the prevalence and types of DRAs identified by STOPP/START.v1 and STOPP/START.v2. METHODS: We applied the STOPP/START.v2 criteria to a subset of 100 consecutively admitted geriatric patients selected from our original cross-sectional study of 302 patients. A geriatrician and a pharmacist adjudicated whether the identified PIMs and PPOs were related to acute hospitalization. Admissions were defined as DRAs if the identified PIM(s) and/or PPO(s) were related to the main cause of admission or played a significant contributory role in the admission. RESULTS: The median patient age was 83 years and the median number of medications at home was 8. Compared with STOPP/START.v1, STOPP/START.v2 not only yielded more instances of inappropriate prescribing but also targeted significantly more PIMs and PPOs associated with preventable DRAs (23% vs. 40% of all admissions, p < 0.001). PIMs of fall-risk-increasing drugs, and PPOs of musculoskeletal and cardiovascular system drugs, were most frequently associated with DRAs. CONCLUSION: The latter instances of inappropriate prescribing with major clinical relevance warrant particular attention during medication review in older persons.
BACKGROUND: Older persons are at significant risk of drug-related admissions (DRAs). We previously demonstrated that 27% of hospitalizations in geriatric patients were associated with potentially inappropriate medicines (PIMs) and/or potential prescribing omissions (PPOs) identified by the Screening Tool of Older People's Prescriptions/Screening Tool to Alert to Right Treatment (STOPP/START) criteria version 1 (v1). The updated STOPP/START criteria version 2 (v2) comprised a 31% increase in prescribing criteria. OBJECTIVE: As a secondary analysis of our study conducted in 2008, we aimed to compare the prevalence and types of DRAs identified by STOPP/START.v1 and STOPP/START.v2. METHODS: We applied the STOPP/START.v2 criteria to a subset of 100 consecutively admitted geriatric patients selected from our original cross-sectional study of 302 patients. A geriatrician and a pharmacist adjudicated whether the identified PIMs and PPOs were related to acute hospitalization. Admissions were defined as DRAs if the identified PIM(s) and/or PPO(s) were related to the main cause of admission or played a significant contributory role in the admission. RESULTS: The median patient age was 83 years and the median number of medications at home was 8. Compared with STOPP/START.v1, STOPP/START.v2 not only yielded more instances of inappropriate prescribing but also targeted significantly more PIMs and PPOs associated with preventable DRAs (23% vs. 40% of all admissions, p < 0.001). PIMs of fall-risk-increasing drugs, and PPOs of musculoskeletal and cardiovascular system drugs, were most frequently associated with DRAs. CONCLUSION: The latter instances of inappropriate prescribing with major clinical relevance warrant particular attention during medication review in older persons.
Authors: Shobha Phansalkar; Jennifer M Hoffman; Jonathan R Nebeker; John F Hurdle Journal: Am J Health Syst Pharm Date: 2007-04-15 Impact factor: 2.637
Authors: Anne Spinewine; Kenneth E Schmader; Nick Barber; Carmel Hughes; Kate L Lapane; Christian Swine; Joseph T Hanlon Journal: Lancet Date: 2007-07-14 Impact factor: 79.321
Authors: Denis O'Mahony; David O'Sullivan; Stephen Byrne; Marie Noelle O'Connor; Cristin Ryan; Paul Gallagher Journal: Age Ageing Date: 2014-10-16 Impact factor: 10.668
Authors: S Greten; J I Müller-Funogea; O Krause; M Klietz; F Wegner; G U Höglinger; N Simon; U Junius-Walker; S Gerbel Journal: J Neural Transm (Vienna) Date: 2020-12-01 Impact factor: 3.575
Authors: Birgit A Damoiseaux-Volman; Kimmy Raven; Danielle Sent; Stephanie Medlock; Johannes A Romijn; Ameen Abu-Hanna; Nathalie van der Velde Journal: Age Ageing Date: 2022-01-06 Impact factor: 10.668